LeonaBio

Andrée-Anne Berthiaume, Jewel L. Johnston, Sherif Reda, Hans J. Moebius, Kevin J. Church

LeonaBio’s approach targets restoring and maintaining nerve cell connections to address neurological diseases and their impact on patients’ personal relationships.

Javier joined LeonaBio in April 2024 as Chief Medical Officer, offering over 25 years of experience in drug development and global commercialization strategies.

Kevin joined LeonaBio as Chief Scientific Officer in January 2023, bringing over a decade of experience in life sciences research and drug development.

Mark joined LeonaBio in 2024 as a strategic consultant and was appointed Chief Business Officer in February 2026, with over 25 years in biopharmaceutical business development.

Mark serves as President and CEO of LeonaBio, a role he has held since October 2021. He previously led the company as COO from July 2019 and held similar positions at Alpine Immune Sciences and Alder Biopharmaceutical.

Mark Litton, PhD President & Chief Executive Officer

Athira focuses on restoring nerve cell connections to treat neurological diseases, aiming to improve both cellular and personal connections for patients.

Athira is a late clinical-stage biopharmaceutical company developing small molecules to restore neuronal health and halt neurodegeneration, including its lead candidate ATH-1017 for Alzheimer’s.

18706 North Creek Parkway Suite 104 Bothell, WA 98011

LeonaBio’s lead drug candidates, lasofoxifene and brelgometon (ATH-1105), are small molecule therapies targeting diseases with limited treatment options.

LeonaBio develops novel therapeutics for diseases with high unmet needs, including amyotrophic lateral sclerosis (ALS) and treatment-resistant metastatic breast cancer.